Posted by Michael Wonder on 19 Jul 2022
Peptilogics receives FDA fast track designation for PLG0206, an investigational peptide therapeutic in development for the treatment of peri-prosthetic joint infection
19 July 2022 - PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment of peri-prosthetic joint infection.
Peptilogics today announced that the U.S. FDA has granted fast track designation to the company’s lead drug candidate, PLG0206, for the treatment of peri-prosthetic joint infection.
